First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.

被引：17

作者：

Ameratunga, Malaka

Harvey, R. Donald

Mau-Sorensen, Morten

Thistlethwaite, Fiona

Forssmann, Ulf

Gupta, Manish

Johannsdottir, Hrefna

Ramirez-Andersen, Terrie

Bohlbro, Mika Linette

Losic, Nedjad

Ervin-Haynes, Annette L.

Lopez, Juanita Suzanne

Vergote, Ignace

机构：

[1] Alfred Hosp, Melbourne, Vic, Australia

[2] Emory Univ, Sch Med, Atlanta, GA USA

[3] Rigshosp, Copenhagen, Denmark

[4] Christie NHS Fdn Trust, Manchester, Lancs, England

[5] Univ Manchester, Manchester, Lancs, England

[6] Genmab AS, Copenhagen, Denmark

[7] Genmab AS, Princeton, NJ USA

[8] Royal Marsden Hosp, London, England

[9] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.2525

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2525

引用

页数：2